Targeting a cause of GPP | SPEVIGO® (spesolimab-sbzo)

Unlocking a treatment for generalized pustular psoriasis

Keyhole with fire symbolizing IL-36 pathway imbalance in GPP

The barrier:
an imbalance in the IL-36 pathway

GPP, or generalized pustular psoriasis, is caused by an imbalance in a part of your immune system known as the interleukin-36 (or IL-36) pathway. When this pathway is out of balance, your body experiences ongoing and potentially life-threatening inflammation.

Gold key with GPP letters symbolizing how treatment works

The key:
how SPEVIGO works

SPEVIGO is the first FDA-approved therapy for GPP. It helps control the activity of the IL-36 pathway, targeting GPP inflammation within the body, including the skin.

Other diseases, like plaque psoriasis, are primarily caused by different pathways, including IL-17 and IL-23. Treatments that impact the IL-17 or IL-23 pathways may not treat GPP.

SPEVIGO is a type of treatment known as a biologic. It works within the body to target and address a specific part of the IL-36 pathway that causes inflammation in GPP. The precise way IL-36 activity may impact the treatment of GPP flares is not fully understood.

What happens inside the body with SPEVIGO

See how SPEVIGO works to help reduce the inflammation that causes GPP symptoms.

SC=subcutaneous.

SPEVIGO SC is a monthly treatment for GPP when not experiencing a flare

EXPLORE THE RESULTS

Indication

SPEVIGO is a prescription medicine used to treat generalized pustular psoriasis (GPP) in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg). It is not known if SPEVIGO is safe and effective in children under 12 years of age or who weigh less than 88 pounds (40 kg).

Please see the full Prescribing Information, including Medication Guide and Instructions for Use.

Important Safety Information
and Indication

Do not receive SPEVIGO if you or your child have had a severe or life-threatening allergic reaction to spesolimab-sbzo or any of the ingredients in SPEVIGO.

SPEVIGO may cause serious side effects, including:

Infections: SPEVIGO may lower the ability of your or your child’s immune system to fight infections and may increase your or your child’s risk of infections. Your healthcare provider should check you or your child for infections and tuberculosis (TB) before starting treatment with SPEVIGO and may treat you or your child for TB before you begin treatment with SPEVIGO if you have a history of TB or have active TB. Your healthcare provider should watch you or your child closely for signs and symptoms of TB during or after treatment with SPEVIGO. Tell your healthcare provider right away if you or your child have an infection or have symptoms of an infection during or after treatment with SPEVIGO, including, fevers, chills, or sweats, muscle aches, cough, shortness of breath, blood in your phlegm (mucus), burning when you urinate, urinating more often than normal
Allergic reactions and infusion-related reactions: Serious allergic reactions may happen during or after your or your child’s SPEVIGO injection. If you or your child have a serious allergic reaction, your healthcare provider will stop treatment with SPEVIGO. If you or your child are given SPEVIGO in a vein (intravenously) and have an infusion-related reaction, your healthcare provider will stop your or your child’s SPEVIGO infusion and treat your or your child’s symptoms and may restart SPEVIGO at a slower infusion rate. Tell your healthcare provider or get emergency medical help right away if you or your child get any of the following symptoms during or after your or your child’s SPEVIGO injection: feeling faint, dizzy, or lightheaded, swelling of your face, eyelids, lips, mouth, tongue, or throat, trouble breathing or throat tightness, fever, mouth sores, chest tightness, hives or skin rash that is different than the rash from generalized pustular psoriasis (GPP), itching, swollen lymph nodes

Before you or your child receive SPEVIGO, tell your healthcare provider about all of your medical conditions, including if you or your child:

have an infection that does not go away or that keeps coming back.
have TB or have been in close contact with someone with TB.
have recently received or are scheduled to receive an immunization (vaccine). You or your child should not receive live vaccines during and for at least 16 weeks after treatment with SPEVIGO. You or your child should be brought up to date with all vaccines before starting SPEVIGO.
are pregnant or plan to become pregnant. It is not known if SPEVIGO can harm your or your child’s unborn baby.
are breastfeeding or plan to breastfeed. It is not known if SPEVIGO passes into your breast milk. Talk to your healthcare provider about the best way to feed your or your child’s baby during treatment with SPEVIGO.

The most common side effects of SPEVIGO given in a vein (intravenously) for GPP flare treatment include feeling tired or weak, headache, nausea, itching or itchy bumps, a collection of blood under the skin at the infusion site or bruising, urinary tract infection

The most common side effects of SPEVIGO when given under the skin (subcutaneously) for treatment of GPP when not experiencing a flare include redness, pain, swelling, hardening, hives, or warmth at the injection site, joint pain, urinary tract infection, itching

These are not all of the possible side effects of SPEVIGO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see the full Prescribing Information, including Medication Guide and Instructions for Use.

Read more Collapse